High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: A report from the Children's Oncology Group
- 17 August 2013
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (12) , 2042-2046
Abstract
Background Body mass index (BMI), at diagnosis has been associated with lower survival and increased toxicity in cancer patients. We analyzed the effect of BMI at diagnosis on therapy related toxicities and outcome in pediatric osteosarcoma patients treated on Children's Oncology Group (COG) trial INT0133. Procedures All patients enrolled on COG‐INT0133 with height, weight and toxicity information were eligible. BMI was expressed as age and gender specific percentiles using height and weight at diagnosis. Patients were classified into high, normal and low BMI groups. Logistic regression models were used to analyze toxicities; Kaplan–Meier curves were created to assess event free (EFS) and overall survival (OAS). Results Seven hundred and ten patients met eligibility criteria. BMI distribution was: 447 normal BMI, 74 low BMI, and 189 high BMI. Renal toxicity was higher in the high BMI group (OR = 2.7, 95% CI 1.2–6.4, P = 0.01) only during one of the courses of therapy. Compared to the normal BMI group, patients with high BMI had significantly worse OAS at 5 years compared to those with normal BMI, 69.7% versus 80.5% (HR = 1.6, 95% CI 1.1–2.2, P = 0.005) and a trend towards worse event‐free survival at 3 years 66.2% versus 75.5% (HR = 1.3 95% CI 0.9–1.8, P = 0.05). There was no difference in EFS or OAS in patients with low BMI compared to patients with normal BMI. Conclusions High BMI at diagnosis is associated with worse OAS in patients with osteosarcoma. No clinically significant differences in toxicity were observed in the various BMI groups. Pediatr Blood Cancer 2013;60:2042–2046.Keywords
This publication has 18 references indexed in Scilit:
- Effect of body mass index on the outcome of children with acute myeloid leukemiaCancer, 2012
- Children's Oncology Group (COG) Nutrition CommitteePediatric Blood & Cancer, 2008
- Obesity and Outcome in Pediatric Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2007
- Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of OsteosarcomaCurrent Cancer Drug Targets, 2006
- Epidemiologic aspects of overweight and obesity in the United States☆Physiology & Behavior, 2005
- Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose MethotrexateJournal of Clinical Oncology, 2005
- Mortality in Overweight and Underweight Children With Acute Myeloid LeukemiaJAMA, 2005
- Impact of Body Mass Index on Outcomes and Treatment-Related Toxicity in Patients With Stage II and III Rectal Cancer: Findings From Intergroup Trial 0114Journal of Clinical Oncology, 2004
- Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantationTransplantation and Cellular Therapy, 1999
- Impact of obesity on allogeneic stem cell transplant patients: A matched case-controlled studyThe American Journal of Medicine, 1997